Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDGN 201

Next Previous
Drug Profile

MDGN 201

Alternative Names: Epodure™; Erythropoietin gene therapy - Aevi Genomic Medicine; MDGN 201 TARGTepo secreting EPO; MDGN-201; TARGTEPO

Latest Information Update: 29 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medgenics
  • Developer Aevi Genomic Medicine
  • Class Antianaemics; Erythropoietins; Gene therapies
  • Mechanism of Action Erythropoiesis stimulants; Gene transference; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anaemia; Beta-thalassaemia; Myelodysplastic syndromes

Most Recent Events

  • 31 Aug 2018 Discontinued - Phase-II for Anaemia (In the elderly, In adults) in USA (SC)
  • 31 Aug 2018 Discontinued - Phase-II for Anaemia in Israel (SC)
  • 31 Aug 2018 Discontinued - Preclinical for Beta-thalassaemia in Israel (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top